Base de datos : MEDLINE
Búsqueda : sida or vih [Palabras]
Referencias encontradas : 293933 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 29394 va a la página                         

  1 / 293933 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:26791918
[Au] Autor:Ankouane F; Noah Noah D; Atangana MM; Kamgaing Simo R; Guekam PR; Biwolé Sida M
[Ad] Dirección:Faculté de médecine et des sciences biomédicales, université de Yaoundé 1, centre hospitalier et universitaire de Yaoundé, Yaoundé, Cameroun. Electronic address: ankouaneandoulo@yahoo.com....
[Ti] Título:[Seroprevalence of hepatitis B and C viruses, HIV-1/2 and syphilis among blood donors in the Yaoundé Central Hospital in the centre region of Cameroon].
[Ti] Título:Séroprévalence des virus des hépatites B et C, du VIH-1/2 et de la syphilis chez les donneurs de sang de l'hôpital central de Yaoundé, région du centre, Cameroun..
[So] Fuente:Transfus Clin Biol;23(2):72-7, 2016 May.
[Is] ISSN:1953-8022
[Cp] País de publicación:France
[La] Idioma:fre
[Ab] Resumen:OBJECTIVES: Prevention of blood transfusion-transmitted infections includes blood donor screening and effective infectious markers screening for donated blood. This study had two main objectives: to determine seroprevalence of HBV, HCV, HIV and syphilis in blood donors of the Yaoundé Central Hospital and to study sociodemographic factors of blood donors. PATIENTS AND METHODS: A retrospective study of consecutive blood donors' records from January to December 2013 was conducted. Seroprevalence of hepatitis B, hepatitis C, human immunodeficiency viruses and syphilis were determined in 9024 whole blood donations collected in the Yaoundé Central Hospital in the centre region, Cameroon using Elisa kits. RESULTS: Mean age of donors was 28 years. The male to female ratio was 14.8. Most of blood donors were replacement donors (97.2%) and first-time donors (76.8%). Up to 19.3% of the donors tested positive for at least one infectious agent, in which 0.1% presented a positive test for three viruses (HIV, HCV and HBV). The overall seroprevalence in blood donors was 12.6% for HBsAg, 3.2% for hepatitis C antibody, 3.3% for HIV-1/2 antibodies and 0.2% for syphilis. The prevalence of HBsAg was significantly higher in men (P=0.001), among first-time donors (P=0.003), in blood group A (P=0.01) and those with the rhesus positive blood (P=0.01). The prevalence of anti-HCV was significantly higher among first-time donors (P=0.05). The prevalence of anti-HIV was significantly higher in first-time donors (3.7% vs 2.2%, P=0.02). CONCLUSION: First-time blood donors and replacement donors are the two types of donors in Cameroon. Replacement donors are considered as having a major risk of transmission of infections to recipients. The seroprevalence of HIV, HBV, HCV, and syphilis among these donors is high and reflects how much these agents are present in Cameroon. Effective infectious markers screening and organization of blood donors into an association of volunteer's donors are necessary to secure blood transfusion in Cameroon.
[Pt] Tipo de publicación:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Mes de ingreso:1606
[Sb] Subgrupo de revista:IM
[St] Status:In-Data-Review


  2 / 293933 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:26681660
[Au] Autor:Seck M; Dièye B; Guèye YB; Faye BF; Senghor AB; Toure SA; Dieng N; Sall A; Toure AO; Dièye TN; Diop S
[Ad] Dirección:Centre national de transfusion sanguine, BP 5002, Dakar, Fann, Sénégal; Service d'hématologie, université Cheikh Anta Diop, BP 5002, Dakar, Fann, Sénégal....
[Ti] Título:[Evaluation of the efficacy of medical screening of blood donors on preventing blood transfusion-transmitted infectious agents].
[Ti] Título:Évaluation de l'efficacité de la sélection médicale des donneurs de sang dans la prévention des agents infectieux..
[So] Fuente:Transfus Clin Biol;23(2):98-102, 2016 May.
[Is] ISSN:1953-8022
[Cp] País de publicación:France
[La] Idioma:fre
[Ab] Resumen:BACKGROUND: The aim of this study was to evaluate the efficacy of medical screening to retain blood donors in window period by comparing the seroprevalence of infectious agents (HIV, hepatitis B and C, syphilis) in deferred versus accepted blood donors. MATERIALS AND METHODS: This prospective and transversal study was performed during 4 months in the National Blood Transfusion Center in Dakar (Senegal). We conducted a convenience sampling comparing the seroprevalence of infectious agents (HIV, HBsAg, HCV and syphilis) in deferred versus accepted blood donors after medical selection. RESULTS: In total, 8219 blood donors were included. Medical selection had authorized 8048 donors (97.92%) and deferred donors were 171 (2.08%). The prevalence of HIV was higher in the deferred than in accepted blood donors (1.75% vs. 0.05%) (P=0.0003; OR=35.91), as well as for HBsAg (12.87% vs. 7.35%) (P=0.006; OR=1.86). HCV antibodies were present in 0.71% of accepted blood donors and 0.58% in deferred blood donors (P=0.65; OR=0.82). Only accepted donors had brought the infection of syphilis (0.34%) (P=0.56; OR=0). CONCLUSION: Medical selection is efficient to exclude blood donors at high risk of HIV transmission and to a lesser extent of HBV. However, current medical screening procedures do not allow us to exclude donors asymptomatic carriers of HCV and syphilis.
[Pt] Tipo de publicación:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Mes de ingreso:1606
[Sb] Subgrupo de revista:IM
[St] Status:In-Data-Review


  3 / 293933 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:26408357
[Au] Autor:Saldanha IJ; Li T; Yang C; Ugarte-Gil C; Rutherford GW; Dickersin K
[Ad] Dirección:Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Room W6507-B, Baltimore, MD 21205, USA. Electronic address: isaldan1@jhmi.edu....
[Ti] Título:Social network analysis identified central outcomes for core outcome sets using systematic reviews of HIV/AIDS.
[So] Fuente:J Clin Epidemiol;70:164-75, 2016 Feb.
[Is] ISSN:1878-5921
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:OBJECTIVES: Methods to develop core outcome sets, the minimum outcomes that should be measured in research in a topic area, vary. We applied social network analysis methods to understand outcome co-occurrence patterns in human immunodeficiency virus (HIV)/AIDS systematic reviews and identify outcomes central to the network of outcomes in HIV/AIDS. STUDY DESIGN AND SETTING: We examined all Cochrane reviews of HIV/AIDS as of June 2013. We defined a tie as two outcomes (nodes) co-occurring in ≥2 reviews. To identify central outcomes, we used normalized node betweenness centrality (nNBC) (the extent to which connections between other outcomes in a network rely on that outcome as an intermediary). We conducted a subgroup analysis by HIV/AIDS intervention type (i.e., clinical management, biomedical prevention, behavioral prevention, and health services). RESULTS: The 140 included reviews examined 1,140 outcomes, 294 of which were unique. The most central outcome overall was all-cause mortality (nNBC = 23.9). The most central and most frequent outcomes differed overall and within subgroups. For example, "adverse events (specified)" was among the most central but not among the most frequent outcomes, overall. CONCLUSION: Social network analysis methods are a novel application to identify central outcomes, which provides additional information potentially useful for developing core outcome sets.
[Mh] Términos MeSH primario: Síndrome de Inmunodeficiencia Adquirida/epidemiología
Infecciones por VIH/epidemiología
Evaluación de Resultado (Atención de Salud)
Literatura de Revisión como Asunto
Apoyo Social
[Mh] Términos MeSH secundario: Síndrome de Inmunodeficiencia Adquirida/mortalidad
Infecciones por VIH/mortalidad
Humanos
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mes de ingreso:1606
[Cu] Fecha actualización por clase:160610
[Lr] Fecha última revisión:160610
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:160129
[St] Status:MEDLINE


  4 / 293933 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:26785991
[Au] Autor:Haukoos JS; Rowan SE
[Ad] Dirección:Department of Emergency Medicine, Denver Health Medical Center, 777 Bannock Street, Mail Code 0108, Denver, CO, 80204 USA Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO Department of Epidemiology, Colorado School of Public Health, Aurora Jason.Haukoos@dhha.org.
[Ti] Título:Screening for HIV infection.
[So] Fuente:BMJ;532:i1, 2016.
[Is] ISSN:1756-1833
[Cp] País de publicación:England
[La] Idioma:eng
[Mh] Términos MeSH primario: Conducta de Elección
Infecciones por VIH/diagnóstico
Tamizaje Masivo/utilización
Aceptación de la Atención de Salud
Prioridad del Paciente
[Mh] Términos MeSH secundario: Femenino
Humanos
Masculino
[Pt] Tipo de publicación:COMMENT; EDITORIAL
[Em] Mes de ingreso:1605
[Cu] Fecha actualización por clase:160610
[Lr] Fecha última revisión:160610
[Sb] Subgrupo de revista:AIM; IM
[Da] Fecha de ingreso para procesamiento:160120
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.i1


  5 / 293933 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:26338421
[Au] Autor:Peebles K; Nchimba L; Chilengi R; Bolton Moore C; Mubiana-Mbewe M; Vinikoor MJ
[Ad] Dirección:Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA peebles.kathryn@gmail.com....
[Ti] Título:Pediatric HIV-HBV Coinfection in Lusaka, Zambia: Prevalence and Short-Term Treatment Outcomes.
[So] Fuente:J Trop Pediatr;61(6):464-7, 2015 Dec.
[Is] ISSN:1465-3664
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:Hepatitis B virus (HBV) is endemic in Africa, where it may occur as an HIV coinfection. Data remain limited on HIV-HBV epidemiology in Africa, particularly in children. Using programmatic data from pediatric HIV clinics in Lusaka, Zambia during 2011-2014, we analyzed the prevalence of chronic HBV coinfection (defined as a single positive hepatitis B surface antigen [HBsAg] test) and its impact on immune recovery and liver enzyme elevation (LEE) during the first year of antiretroviral therapy. Among 411 children and adolescents, 10.4% (95% confidence interval, 7.6-14.1) had HIV-HBV. Coinfected patients were more likely to have World Health Organization stage 3/4, LEE and CD4 <14% at care entry (all p < 0.05). During treatment, CD4 increases and LEE incidence were similar by HBsAg status. HBsAg positivity decreased (11.8% vs. 6.6%; p = 0.24) following HBV vaccine introduction. These findings support screening pediatric HIV patients in Africa for HBV coinfection. Dedicated cohorts are needed to assess long-term outcomes of coinfection.
[Mh] Términos MeSH primario: Fármacos Anti-VIH/uso terapéutico
Coinfección/quimioterapia
Infecciones por VIH/quimioterapia
Hepatitis B Crónica/epidemiología
[Mh] Términos MeSH secundario: Adolescente
Terapia Antirretroviral Altamente Activa
Recuento de Linfocito CD4
Niño
Preescolar
Estudios de Cohortes
Coinfección/epidemiología
Coinfección/virología
ADN Viral/análisis
Femenino
Infecciones por VIH/epidemiología
Infecciones por VIH/virología
VIH-1/efectos de drogas
Antígenos de Superficie de la Hepatitis B
Virus de la Hepatitis B/genética
Hepatitis B Crónica/diagnóstico
Hepatitis B Crónica/virología
Humanos
Lactante
Recién Nacido
Masculino
Prevalencia
Transaminasas/sangre
Resultado del Tratamiento
Zambia/epidemiología
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nombre de substancia:
0 (Anti-HIV Agents); 0 (DNA, Viral); 0 (Hepatitis B Surface Antigens); EC 2.6.1.- (Transaminases)
[Em] Mes de ingreso:1604
[Cu] Fecha actualización por clase:160610
[Lr] Fecha última revisión:160610
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:151202
[St] Status:MEDLINE
[do] DOI:10.1093/tropej/fmv058


  6 / 293933 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
PubMed Central Texto completo
Texto completo
[PMID]:26506854
[Au] Autor:Meressa D; Hurtado RM; Andrews JR; Diro E; Abato K; Daniel T; Prasad P; Prasad R; Fekade B; Tedla Y; Yusuf H; Tadesse M; Tefera D; Ashenafi A; Desta G; Aderaye G; Olson K; Thim S; Goldfeld AE
[Ad] Dirección:Global Health Committee and Zahara Children's Program, Addis Ababa, Ethiopia St. Peter's Tuberculosis Specialized Hospital, Addis Ababa, Ethiopia....
[Ti] Título:Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia--an observational cohort study.
[So] Fuente:Thorax;70(12):1181-8, 2015 Dec.
[Is] ISSN:1468-3296
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: In Africa, fewer than half of patients receiving therapy for multidrug-resistant TB (MDR TB) are successfully treated, with poor outcomes reported for HIV-coinfected patients. METHODS: A standardised second-line drug (SLD) regimen was used in a non-governmental organisation-Ministry of Health (NGO-MOH) collaborative community and hospital-based programme in Ethiopia that included intensive side effect monitoring, adherence strategies and nutritional supplementation. Clinical outcomes for patients with at least 24 months of follow-up were reviewed and predictors of treatment failure or death were evaluated by Cox proportional hazards models. RESULTS: From February 2009 to December 2014, 1044 patients were initiated on SLD. 612 patients with confirmed or presumed MDR TB had ≥ 24 months of follow-up, 551 (90.0%) were confirmed and 61 (10.0%) were suspected MDR TB cases. 603 (98.5%) had prior TB treatment, 133 (21.7%) were HIV coinfected and median body mass index (BMI) was 16.6. Composite treatment success was 78.6% with 396 (64.7%) cured, 85 (13.9%) who completed treatment, 10 (1.6%) who failed, 85 (13.9%) who died and 36 (5.9%) who were lost to follow-up. HIV coinfection (adjusted HR (AHR): 2.60, p<0.001), BMI (AHR 0.88/kg/m(2), p=0.006) and cor pulmonale (AHR 3.61, p=0.003) and confirmed MDR TB (AHR 0.50, p=0.026) were predictive of treatment failure or death. CONCLUSIONS: We report from Ethiopia the highest MDR TB treatment success outcomes so far achieved in Africa, in a setting with severe resource constraints and patients with advanced disease. Intensive treatment of adverse effects, nutritional supplementation, adherence interventions and NGO-MOH collaboration were key strategies contributing to success. We argue these approaches should be routinely incorporated into programmes.
[Mh] Términos MeSH primario: Tuberculosis Resistente a Múltiples Medicamentos/terapia
[Mh] Términos MeSH secundario: Adulto
Coinfección
Etiopía
Femenino
Infecciones por VIH/epidemiología
Humanos
Masculino
Cumplimiento de la Medicación
Modelos de Riesgos Proporcionales
Resultado del Tratamiento
Tuberculosis Resistente a Múltiples Medicamentos/quimioterapia
Tuberculosis Resistente a Múltiples Medicamentos/epidemiología
Tuberculosis Resistente a Múltiples Medicamentos/mortalidad
Adulto Joven
[Pt] Tipo de publicación:JOURNAL ARTICLE; OBSERVATIONAL STUDY; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Em] Mes de ingreso:1603
[Cu] Fecha actualización por clase:160610
[Lr] Fecha última revisión:160610
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:151114
[St] Status:MEDLINE
[do] DOI:10.1136/thoraxjnl-2015-207374


  7 / 293933 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:26258570
[Au] Autor:Lesko CR; Sampson LA; Miller WC; Clymore J; Leone PA; Swygard H; Powers KA
[Ad] Dirección:*Department of Epidemiology, University of North Carolina, Chapel Hill, NC; †Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; ‡Department of Medicine, University of North Carolina, Chapel Hill, NC; and §Communicable Disease Branch, North Carolina Division of Public Health, Raleigh, NC.
[Ti] Título:Measuring the HIV Care Continuum Using Public Health Surveillance Data in the United States.
[So] Fuente:J Acquir Immune Defic Syndr;70(5):489-94, 2015 Dec 15.
[Is] ISSN:1944-7884
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:The HIV care continuum is a critical framework for situational awareness of the HIV epidemic; yet challenges to accurate enumeration of continuum components hamper continuum estimation in practice. We describe local surveillance-based estimation of the HIV continuum in the United States, reviewing common practices as recommended by the Centers for Disease Control and Prevention. Furthermore, we review some challenges and biases likely to threaten existing continuum estimates. Current estimates rely heavily on the use of CD4 cell count and HIV viral load laboratory results reported to surveillance programs as a proxy for receipt of HIV-related outpatient care. As such, continuum estimates are susceptible to bias because of incomplete laboratory reporting and imperfect sensitivity and specificity of laboratory tests as a proxy for routine HIV care. Migration of HIV-infected persons between jurisdictions also threatens the validity of continuum estimates. Data triangulation may improve but not fully alleviate biases.
[Mh] Términos MeSH primario: Continuidad de la Atención al Paciente/normas
Infecciones por VIH/epidemiología
Infecciones por VIH/terapia
[Mh] Términos MeSH secundario: Fármacos Anti-VIH/administración & dosificación
Femenino
Infecciones por VIH/diagnóstico
Humanos
Masculino
Vigilancia de la Población
Informática en Salud Pública
Estados Unidos/epidemiología
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nombre de substancia:
0 (Anti-HIV Agents)
[Em] Mes de ingreso:1602
[Cu] Fecha actualización por clase:160610
[Lr] Fecha última revisión:160610
[Sb] Subgrupo de revista:IM; X
[Da] Fecha de ingreso para procesamiento:151114
[St] Status:MEDLINE
[do] DOI:10.1097/QAI.0000000000000788


  8 / 293933 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:25346056
[Au] Autor:Norton B; Naggie S
[Ad] Dirección:Department of Medicine, Montefiore Medical Center, Bronx, NY, USA. bnorton@montefiore.org.
[Ti] Título:The clinical management of HCV in the HIV-infected patient.
[So] Fuente:Antivir Ther;20(5):457-67, 2015.
[Is] ISSN:2040-2058
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:Chronic hepatitis C affects an estimated 170 million persons worldwide and due to shared transmission routes many persons are coinfected with HIV. Since the advent of HAART, HIV patients have longer life expectancy and suffer fewer AIDS-related complications. The result has been an increase in morbidity and mortality from HIV-associated non-AIDS conditions, with high rates of liver-related deaths resulting from HCV in the coinfected population. Coinfection with HIV is an independent predictor of liver disease progression, and proper staging of fibrosis is of critical importance in the coinfected patient. In contrast to HIV, it is possible to eradicate HCV infection; and undetectable viral load 12 weeks after cessation of therapy, or sustained viral response (SVR), is considered a clinical cure. As achievement of SVR has been associated with significantly reduced mortality from liver disease and liver disease complications, it is imperative that patients coinfected with HIV-HCV receive therapy for their HCV infection. The length of therapy with previously available interferon-based regimens added a significant burden to HIV-HCV-coinfected patients. Newer, all-oral, interferon-free regimens promise to simplify treatment regimens, reduce side-effect profiles, and demonstrate reduced drug interactions with numerous HAART regimens.
[Mh] Términos MeSH primario: Antivirales/uso terapéutico
Interacciones de Drogas
Infecciones por VIH/quimioterapia
Hepatitis C Crónica/quimioterapia
Hígado/patología
[Mh] Términos MeSH secundario: Coinfección/quimioterapia
Coinfección/mortalidad
Progresión de la Enfermedad
Quimioterapia Combinada
Diagnóstico por Imagen de Elasticidad
Infecciones por VIH/complicaciones
Hepatitis C Crónica/complicaciones
Hepatitis C Crónica/transmisión
Humanos
Hígado/virología
Cirrosis Hepática/patología
Cirrosis Hepática/virología
Carga Viral
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; REVIEW
[Nm] Nombre de substancia:
0 (Antiviral Agents)
[Em] Mes de ingreso:1605
[Cu] Fecha actualización por clase:160610
[Lr] Fecha última revisión:160610
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:151021
[St] Status:MEDLINE
[do] DOI:10.3851/IMP2910


  9 / 293933 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
PubMed Central Texto completo
Texto completo
[PMID]:26469928
[Au] Autor:Green N; Hoenigl M; Morris S; Little SJ
[Ad] Dirección:From the Division of Infectious Diseases, Department of Medicine, University of California San Diego (UCSD) (NG, MH, SM, SJL); Division of Family Medicine, University of California San Diego (UCSD), San Diego, CA (SM); Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine (MH); and Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria (MH).
[Ti] Título:Risk Behavior and Sexually Transmitted Infections Among Transgender Women and Men Undergoing Community-Based Screening for Acute and Early HIV Infection in San Diego.
[So] Fuente:Medicine (Baltimore);94(41):e1830, 2015 Oct.
[Is] ISSN:1536-5964
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:The transgender community represents an understudied population in the literature. The objective of this study was to compare risk behavior, and HIV and sexually transmitted infection (STI) rates between transgender women and transgender men undergoing community-based HIV testing.With this retrospective analysis of a cohort study, we characterize HIV infection rates as well as reported risk behaviors and reported STI in 151 individual transgender women and 30 individual transgender men undergoing community based, voluntary screening for acute and early HIV infection (AEH) in San Diego, California between April 2008 and July 2014.HIV positivity rate was low for both, transgender women and transgender men undergoing AEH screening (2% and 3%, respectively), and the self-reported STI rate for the prior 12 months was 13% for both. Although transgender women appeared to engage in higher rates of risk behavior overall, with 69% engaged in condomless receptive anal intercourse (CRAI) and 11% engaged in sex work, it is important to note that 91% of transgender women reported recent sexual intercourse, 73% had more than 1 sexual partner, 63% reported intercourse with males, 37% intercourse with males and females, and 30% had CRAI.Our results indicate that in some settings rates of HIV infection, as well as rates of reported STIs and sexual risk behavior in transgender men may resemble those found in transgender women. Our findings support the need for comprehensive HIV prevention in both, transgender women and men.
[Mh] Términos MeSH primario: Infecciones por VIH/epidemiología
Asunción de Riesgos
Enfermedades de Transmisión Sexual/epidemiología
Personas Transgénero
[Mh] Términos MeSH secundario: Adulto
California/epidemiología
Femenino
Humanos
Masculino
Tamizaje Masivo
Estudios Retrospectivos
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mes de ingreso:1601
[Cu] Fecha actualización por clase:160610
[Lr] Fecha última revisión:160610
[Sb] Subgrupo de revista:AIM; IM
[Da] Fecha de ingreso para procesamiento:151016
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000001830


  10 / 293933 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:25883388
[Au] Autor:Metcalf Pate KA; Pohlmeyer CW; Walker-Sperling VE; Foote JB; Najarro KM; Cryer CG; Salgado M; Gama L; Engle EL; Shirk EN; Queen SE; Chioma S; Vermillion MS; Bullock B; Li M; Lyons CE; Adams RJ; Zink MC; Clements JE; Mankowski JL; Blankson JN
[Ad] Dirección:Department of Molecular and Comparative Pathobiology....
[Ti] Título:A Murine Viral Outgrowth Assay to Detect Residual HIV Type 1 in Patients With Undetectable Viral Loads.
[So] Fuente:J Infect Dis;212(9):1387-96, 2015 Nov 1.
[Is] ISSN:1537-6613
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Sensitive assays are needed for detection of residual human immunodeficiency virus (HIV) in patients with undetectable plasma viral loads to determine whether eradication strategies are effective. The gold standard quantitative viral outgrowth assay (QVOA) underestimates the magnitude of the viral reservoir. We sought to determine whether xenograft of leukocytes from HIV type 1 (HIV)-infected patients with undetectable plasma viral loads into immunocompromised mice would result in viral amplification. METHODS: Peripheral blood mononuclear cells or purified CD4(+) T cells from HIV or simian immunodeficiency virus (SIV)-infected subjects with undetectable plasma viral loads were adoptively transferred into NOD.Cg-Prkdc(scid)Il2rg(tm1Wjl)/SzJ (NSG) mice. The mice were monitored for viremia following depletion of human CD8(+) T cells to minimize antiviral activity. In some cases, humanized mice were also treated with activating anti-CD3 antibody. RESULTS: With this murine viral outgrowth assay (MVOA), we successfully amplified replication-competent HIV or SIV from all subjects tested, including 5 HIV-positive patients receiving suppressive antiretroviral therapy (ART) and 6 elite controllers or suppressors who were maintaining undetectable viral loads without ART, including an elite suppressor from whom we were unable to recover virus by QVOA. CONCLUSIONS: Our results suggest that the MVOA has the potential to serve as a powerful tool to identify residual HIV in patients with undetectable viral loads.
[Mh] Términos MeSH primario: Infecciones por VIH/diagnóstico
VIH-1/aislamiento & purificación
Carga Viral
[Mh] Términos MeSH secundario: Animales
Terapia Antirretroviral Altamente Activa
Linfocitos T CD4-Positivos/inmunología
Linfocitos T CD8-positivos/inmunología
Linfocitos T CD8-positivos/virología
Modelos Animales de Enfermedad
Infecciones por VIH/quimioterapia
VIH-1/crecimiento & desarrollo
Humanos
Interleucina-2/sangre
Leucocitos Mononucleares/virología
Macaca
Masculino
Ratones
Virus de la Inmunodeficiencia de los Simios/crecimiento & desarrollo
Virus de la Inmunodeficiencia de los Simios/aislamiento & purificación
Viremia/veterinaria
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nombre de substancia:
0 (Interleukin-2)
[Em] Mes de ingreso:1601
[Cu] Fecha actualización por clase:160610
[Lr] Fecha última revisión:160610
[Sb] Subgrupo de revista:AIM; IM
[Da] Fecha de ingreso para procesamiento:151013
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jiv230



página 1 de 29394 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud